Home > Boards > US OTC > Delisted >

Immtech Pharmaceuticals (fka IMMP)

RSS Feed
Add Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/22/2019 5:25:42 PM - Followers: 2 - Board type: Free - Posts Today: 0

Immtech to achieve significant returns by providing cures and preventions for infectious diseases that globally affect millions of people. We target diseases that lend themselves to clearly measurable results in relatively short clinical trials. In addition, we utilize a business model that is distinctive for its cost-effectiveness and attractive partnering potential with leaders in the pharmaceutical industry. Innovative Technology Platform We have an exclusive worldwide license to develop and commercialize compounds based on a proprietary medicinal chemistry platform. These compounds constitute a library that could form a pipeline of products for large, global markets. Our first oral drug candidate, pafuramidine maleate (DB289), targets three acute infectious diseases: Pneumocystis pneumonia (PCP) –a common life-threatening opportunistic infection in AIDS and other immunosuppressed patients such as those on chemotherapy or who have had solid organ transplants Trypanosomiasis –or African sleeping sickness – a parasitic disease spread by tsetse flies in sub-Saharan Africa, threatening 60 million people in 36 countries Malaria –a leading cause of death worldwide, killing over one million people annually, with at least 300 million new cases reported each year (according to the World Health Organization) Pafuramidine is currently in two separate Phase III human clinical trials to treat PCP and Trypanosomiasis. Immtech is also conducting a Phase IIb trial for malaria treatment, and a Phase II trial to determine the appropriate dosing of pafuramidine to prevent malaria. We are encouraged with the progress of our trials and anticipate a successful transition from development to commercialization. Preclinical testing of several new drug candidates to treat hepatitis C (HCV), bacterial infections, and systemic fungal infections is in progress. Scientific Consortium Immtech’s Scientific Consortium is a unique and innovative alliance with an esteemed group of scientists from the University of North Carolina at Chapel Hill (UNC-CH), Georgia State University, and other internationally renowned universities and research institutes. The Scientific Consortium is led by Dr. Richard Tidwell of UNC-CH. The consortium’s scientists have designed and synthesized thousands of compounds to create a large and diverse library. Immtech screens many of these compounds through a wide variety of in vitro assays and in vivo models. Positive results from these screens have provided the foundation for new discovery programs. These capabilities and resources will ultimately enable Immtech to efficiently bring forward new preclinical and clinical drug candidates. These discovery efforts have generated lead optimization drug candidates for treating hepatitis C, bacterial infections and systemic fungal infections. Management Team Eric L. Sorkin Chairman and Chief Executive Officer Mr. Sorkin has 25 years of making strategic investments and business development. He has been affiliated with Immtech since 1998, when he became an investor. In 2000, Mr. Sorkin became a director for the Company, and more recently was appointed Chairman of the Board and CEO. Mr. Sorkin began his career on Wall Street in 1982 working at Dean Witter, which is now a subsidiary of Morgan Stanley, and from an entry-level position, he was promoted to Managing Director within six years. He was among the core group of professionals at the firm, which developed the firm’s investment portfolio with assets of over USD $3 billion. Corporations, banks and entities with which Mr. Sorkin worked on completed transactions included Aetna, International Paper, Continental Insurance, Barclays Banks, Chase Manhattan, Harvard University, Southern Bell, Cigna, the State of Wisconsin, AIG, Modern Woodman of America, Zurich American Life, and San Francisco City and County. Mr. Sorkin was responsible for investment selection, negotiations, transaction and financial structuring, debt placement, and asset management. Mr. Sorkin was Officer of over 20 public investment partnerships with investment funds totaling over USD $1 billion. In 1993, Mr. Sorkin created his own investment firm and began making private equity investments in the U.S. and in China. Mr. Sorkin graduated from Yale University with a B.A. in Economics. Immtech Pharmaceuticals, Inc. (AMEX: IMM) is focused on an opportunity long ignored by large pharmaceutical companies: the development and commercialization of oral drugs to treat infectious diseases in the developed as well as the developing markets. Infectious diseases affect billions of people, and the sales potentials are substantial. Our proprietary medicinal chemistry platform has yielded compounds with demonstrated activity against infectious diseases and other disorders. Our target markets are large: Pneumocystis Pneumonia (PCP) – affects an estimated one million adults and children and threatens 42 million adults and children living with HIV/AIDS. The market for treatment ranges between US$40 and US$50 million, with an estimated US$1.0 billion for PCP prevention. Trypanosomiasis (African sleeping sickness) – threatens an estimated 60 million people in 36 countries in sub-Saharan Africa. Targeted purchasers for treatments will be private foundations and governments. Malaria – infects at least 300 million people each year and kills over a million people annually. The estimated annual market potential is over US$1.0 billion for malaria prevention. We are advancing efforts to commercialize our first drug candidate, pafuramidine maleate (DB289), which is in two separate Phase III clinical trials. We have also initiated a Phase II trial to determine the appropriate dosing of pafuramidine to prevent malaria. We are exploring collaborations for high-profile disease indications to expedite drug development and commercialization. We have capitalized on decades of public and private investment and research efforts by our consortium of scientists who have developed a medicinal chemistry platform and thousands of compounds covered by patents to which we have an exclusive worldwide license. We attract non-dilutive funding from the U.S. government and renowned foundations, which recognize our potential to address severe global health threats. We have a clear path to progress from discovery and development to sales and profitability. Pafuramidine is targeting diseases with urgent, unmet needs. Current therapies have side effects or significant limitations.
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#23   What does this say? From OTCMarkets: IMMP Outstanding 0whammies 03/22/19 05:25:42 PM
#22   ,,,,,,SCREW AMERITRADE....WHAT DOES THIS SAY??? DON'T BE A $$$MADE 03/22/19 04:34:48 PM
#21   From TDA. Does this not say....IMMP Shares Outstanding 33.4M?? 0whammies 03/22/19 04:28:06 PM
#20   DOES THIS NOT SAY 3.03 BILLION https://finance.yahoo.com/quote/IMMP/key-st $$$MADE 03/22/19 04:24:09 PM
#19   TDA shows 33 million. Where do you see 0whammies 03/22/19 01:24:03 PM
#18   PASS....OVER $3B SHARES OS $$$MADE 03/22/19 09:41:32 AM
#17   Busy with ongoing trial data readouts this year: stockguard 03/19/19 05:24:21 PM
#16   Immutep to Present at Upcoming Industry Conferences stockguard 02/26/19 01:59:36 PM
#15   Current FDA clinical trials: stockguard 01/26/19 04:53:42 PM
#14   A drug that activates the protein LAG-3 (Lymphocyte stockguard 01/26/19 04:51:04 PM
#13   IMMP revoked: Renee 01/21/14 10:08:30 AM
#12   IMMP SEC Suspension: Renee 10/31/13 09:39:43 AM
#11   Immtech Appoints Blythe Weigh as Strategic Advisor surf1944 02/13/08 07:29:02 AM
#10   Immtech Investor Conference Call Scheduled for January 3, Teamlasvegas 12/28/07 12:54:21 PM
#9   Shares of Immtech Pharmaceuticals Inc. (IMM) were on Teamlasvegas 12/28/07 12:52:56 PM
#8   Probably not a golden drug.... 10nisman 12/26/07 11:29:34 AM
#7   Immtech Announces Interim Analysis in Phase III African cocktails and dreamz 10/16/07 11:48:43 AM
#6   this is huge imo, cocktails and dreamz 09/29/07 10:53:26 AM
#5   Furamidine Found to Inhibit a Key Enzyme Involved cocktails and dreamz 09/29/07 10:52:31 AM
#4   David Fleet Joins Immtech Board of Directors cocktails and dreamz 09/29/07 10:48:49 AM
#3   US FDA Grants Orphan Drug Status to Immtech's cocktails and dreamz 09/29/07 10:48:01 AM
#2   Chinese SFDA Grants Immtech Fast Track Status cocktails and dreamz 09/29/07 10:46:54 AM
#1   http://www7.nationalgeographic.com/ngm/0707/feature1/ Pretty good reading o cocktails and dreamz 09/29/07 10:44:37 AM
PostSubject